CRSP vs NTLA: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CRSP is the larger of the two ($3.81B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 1.90). NTLA is the smaller challenger ($1.42B), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, CRSP fits: analysts expect its revenue to rise 265% next year, against 176% for NTLA. If you believe NTLA's main driver (Positive Late-Stage Lonvo-z Data in Hereditary Angioedema) pays off sooner, NTLA fits.

CRSP vs NTLA: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCRSPNTLAWhat it tells you
Market cap$3.81B$1.42BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-10.67-3.76Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.901.82Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range4% of range21% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.312.32How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how CRSP and NTLA affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRSP and NTLA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRSP and NTLA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does CRISPR Therapeutics AG (CRSP) do?

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

What does Intellia Therapeutics (NTLA) do?

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing genome-editing therapies based on CRISPR/Cas9. Its core differentiator is a proprietary in vivo platform that delivers the editing machinery directly into the body, typically the liver, using lipid nanoparticles, so that a single dose can permanently inactivate or modify a disease-causing gene without removing cells from the patient. This contrasts with ex vivo approaches that edit cells outside the body and reinfuse them. The company is pre-revenue from products and currently records only collaboration revenue from partners; it funds operations through its cash reserves and periodic capital raises.

Full NTLA guide

CRSP vs NTLA: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.
  • NTLA drivers: Positive Late-Stage Lonvo-z Data in Hereditary Angioedema; In Vivo CRISPR Platform.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $25 million over the twelve months to September 2026. For NTLA, intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value.

CRSP or NTLA: which should you pick?

If the story you believe is CRSP's (First-Mover Advantage in Commercial Gene Editing), CRSP is the more direct way to own it; if it is NTLA's (Positive Late-Stage Lonvo-z Data in Hereditary Angioedema), NTLA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRSP and NTLA guides.

CRSP vs NTLA: the full fundamentals

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based multiples like P/E are negative and not analytically useful; the company is better evaluated on cash runway, Casgevy adoption, and the risk-adjusted value of its pipeline. Market cap of about $3.8 billion less roughly $1.5 billion of net cash leaves an enterprise value near $2.3 billion, down from about $3.3 billion a month earlier, which reflects significant execution uncertainty. Targets remain widely spread, from UBS at $52 to a consensus mean near $85, both well above the November 20 close.

NTLA. Because Intellia has no product profits and only collaboration revenue, earnings-based multiples like P/E are negative and not analytically useful; at about $1.42 billion the market value sits at roughly 2.3 times book. The stock is better evaluated on its cash runway (about $474 million of cash against about $230 million of debt and a trailing operating cash outflow of about $355 million), the probability and timing of approval for lonvo-z (FDA decision due March 10, 2027) and nex-z, and the risk-adjusted commercial potential of those programs. Analysts expect revenue to rise to about $119 million in 2027 with a loss near -$2.70 per share, so dilution and the binary nature of regulatory and trial outcomes stay central to any valuation view.

Headline figures (approximate, November 2026): CRSP shows revenue (ttm to sep 30, 2026) ~$25 million (Q3 2026 ~$12.7 million), revenue (full year 2025) ~$3.5 million, net loss (ttm) ~$456 million; Q3 2026 ~$111 million, eps (q3 2026, actual vs estimate) -$1.15 vs -$1.06; NTLA shows revenue (ttm to sept 2026) ~$53M collaboration revenue; Q3 2026 ~$7.2M (-48% YoY), net loss (ttm) ~$426M; Q3 2026 ~$127M, eps (q3 2026 vs estimate) -$0.91 vs -$0.79, cash / debt ~$474M cash, ~$230M debt (Sept 2026).

The bottom line: CRSP vs NTLA

CRSP and NTLA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CRSP and NTLA exposure against your real portfolio. It is not an investment adviser.

Wondering how CRSP or NTLA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about CRISPR Therapeutics AG

Ask Walnut's AI anything about CRSP and see how it fits what you own.

FAQ

What is the difference between CRSP and NTLA?

+

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. Intellia Therapeutics, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CRSP or NTLA the better stock?

+

Neither is universally better. CRSP is the larger incumbent; NTLA is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CRSP or NTLA?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CRSP and NTLA?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CRSP vs NTLA?

+

CRSP: The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $25 million over the twelve months to September 2026. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. Losses have not yet narrowed in a straight line: the Q3 2026 net loss of about $111 million was wider than Q2's and missed consensus. The convertible notes add about $780 million of debt that will eventually need to be repaid or converted, with dilution risk if conversion happens. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The share price, down about 36% over three months and near its 52-week low even after the November CTX310 update, reflects meaningful skepticism about the pace of the commercial ramp, and binary clinical readouts can move it sharply in either direction. NTLA: Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The company lost about $96 million to $127 million per quarter over the past year (about $426 million over the trailing twelve months to September 2026), with the third quarter of 2026 the largest loss of the four, and has repeatedly raised equity to extend its runway, so existing shareholders face ongoing dilution risk before any product profit materializes. The September 2026 OrbiMed facility of up to $400 million reduces near-term reliance on equity but adds debt that must be serviced and repaid; Yahoo Finance showed total debt of about $230 million at September 30, up from about $73 million in June. A launch, if lonvo-z is approved, also brings new spending on a commercial organization before revenue arrives, and collaboration revenue has been shrinking (about $7.2 million in Q3 2026, down from about $23 million in Q4 2025, and about 48% lower year over year). Even with positive data, regulatory approval, reimbursement, and commercial adoption of a novel one-time gene-editing therapy are uncertain and could take years. The company also competes with better-capitalized CRISPR and gene-editing peers, with RNA-interference and stabilizer drugs already approved in ATTR, and with established prophylaxis options in hereditary angioedema.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CRSP or NTLA; figures are approximate and dated (as of November 2026). Verify current data before investing.